Differential Outcomes with Empagliflozin and Dapagliflozin in Heart Failure with Mildly Reduced Ejection Fraction.

ABSTRACT:

Background

Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure (HF), yet comparative effectiveness between individual agents in heart failure with mildly reduced ejection fraction (HFmrEF) remains limited.

Methods

We conducted a retrospective cohort study using the TriNetX Global Collaborative Network electronic health record database. Adults (≥18 years) with HF and left ventricular ejection fraction (LVEF) 41-49% initiating empagliflozin or dapagliflozin between September 2021 and December 2025 were included. Propensity score matching (1:1) balanced demographics, comorbidities, medications, and laboratory values, yielding 1,466 patients per group. Outcomes were assessed over 1 year after treatment initiation and included all-cause mortality,

SUBMITTER: Mortada I 

PROVIDER: S-EPMC12870609 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature